AI Article Synopsis

  • Hypophosphatasia (HPP) is a genetic disorder that affects bone health, with adult-onset HPP being a milder form that appears after age 18, causing issues like osteomalacia.
  • A case study of a 64-year-old woman with pseudofractures and low alkaline phosphatase levels led to a diagnosis of HPP, confirmed by a specific genetic variant.
  • Treatment with asfotase alfa (AA) resulted in significant improvements in her bone healing and mobility over six months, suggesting that AA is effective for severe HPP cases, while also identifying a new variant in the gene responsible for the disease.

Article Abstract

Hypophosphatasia (HPP) is an inherited disease caused by variants of the gene encoding tissue-nonspecific alkaline phosphatase. Adult-onset HPP (adult HPP), known as a mild form of HPP, develops symptoms involving osteomalacia after the age of 18 years. Asfotase alfa (AA) is a modulated recombinant human alkaline phosphatase (ALP) that has been established as a first-line therapy for severe forms of HPP, such as perinatal and infantile forms. We described a 64-year-old female who presented with pseudofractures in bilateral femur diaphyses and impaired mobility. Low serum ALP activity and a high concentration of urine phosphoethanolamine indicated the diagnosis of HPP, which was confirmed by the identification of a homozygous variant in the gene (c.319G > A; p.Val107Ile). An in vitro transfection experiment to measure the ALP activity of this novel variant protein was performed, resulting in 40% of the residual enzymatic activity compared with the wild type. AA was initiated to facilitate the union of pseudofracture and to improve mobility. After 6 months, radiographic images revealed the disappearance of fracture lines, and improvement of ambulatory ability was confirmed by the 6-minute walk test (525 to 606 m). The EQ-5D-5L index was also improved (0.757 to 0.895). Within a follow-up period, the levels of urine pyrophosphate corrected by urine creatinine (uPPi/Cre) declined in parallel with the level of plasma PPi (plasma PPi: 6.34 to 1.04 μM, uPPi/Cre: 226.8 to 75.4 nmol/mg). The beneficial effect of AA on pseudofracture healing in adult HPP was presented, although the application of AA should be restricted to patients exhibiting relatively severe manifestations. In addition, a novel pathogenic variant of the gene was identified with the supportive result of functional analysis. Furthermore, when monitoring patients with HPP treated with AA, uPPi/Cre might be a convenient substitute for plasma PPi, which requires immediate filtration after blood sampling. © 2023 The Authors. published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10731098PMC
http://dx.doi.org/10.1002/jbm4.10842DOI Listing

Publication Analysis

Top Keywords

plasma ppi
12
asfotase alfa
8
urine pyrophosphate
8
hpp
8
alkaline phosphatase
8
adult hpp
8
alp activity
8
variant gene
8
plasma
4
alfa plasma
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!